T44.5X2A Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter

Billable ICD-10-CM code, FY2026.

Built from T44.5X2 with 7th character A (initial encounter).

Applies from T44 Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system

7th character note

• The appropriate 7th character is to be added to each code from category T44

7th character required

• A — initial encounter
• D — subsequent encounter
• S — sequela

Applies from T44.5 Poisoning by, adverse effect of and underdosing of predominantly beta-adrenoreceptor agonists

Excludes1 (never code together)

• poisoning by, adverse effect of and underdosing of beta-adrenoreceptor agonists used in asthma therapy (T48.6-)

Risk adjustment (HCC)

• CMS-HCC V28: HCC 155 — Major Depression, Moderate or Severe, without Psychosis
• CMS-HCC V22: HCC 58 — Major Depressive, Bipolar, and Paranoid Disorders
• RxHCC V08: HCC 132 — Depression
• ESRD V24: HCC 59

Code annotations containing back-references to T44.5X2A

Back-references to T44.5

• Type 1 Excludes: T48.6 Poisoning by, adverse effect of and underdosing of antiasthmatics, not elsewhere classified ("poisoning by, adverse effect of and underdosing of beta-adrenoreceptor agonists not used in asthma therapy (T44.5)")

Back-references to T44

• Use Additional: D46 Myelodysplastic syndromes ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D52.1 Drug-induced folate deficiency anemia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D59.0 Drug-induced autoimmune hemolytic anemia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D59.2 Drug-induced nonautoimmune hemolytic anemia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D59.39 Other hemolytic-uremic syndrome ("code, if applicable, for adverse effect to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D61.1 Drug-induced aplastic anemia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: D64.2 Secondary sideroblastic anemia due to drugs and toxins ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: D64.2 Secondary sideroblastic anemia due to drugs and toxins ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D70.2 Other drug-induced agranulocytosis ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D72.12 Drug rash with eosinophilia and systemic symptoms syndrome ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: D84.821 Immunodeficiency due to drugs ("code for adverse effect if applicable, to identify adverse effect of drug (T36-T50 with fifth or six character 5)")
• Use Additional: D89.3 Immune reconstitution syndrome ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: E03.2 Hypothyroidism due to medicaments and other exogenous substances ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: E03.2 Hypothyroidism due to medicaments and other exogenous substances ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E06.4 Drug-induced thyroiditis ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: E09 Drug or chemical induced diabetes mellitus ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: E09 Drug or chemical induced diabetes mellitus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E16.0 Drug-induced hypoglycemia without coma ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E22.1 Hyperprolactinemia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E23.1 Drug-induced hypopituitarism ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E24.2 Drug-induced Cushing's syndrome ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E25.8 Other adrenogenital disorders ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E27.3 Drug-induced adrenocortical insufficiency ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E28.0 Estrogen excess ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E28.1 Androgen excess ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E29.1 Testicular hypofunction ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E61 Deficiency of other nutrient elements ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: E66.1 Drug-induced obesity ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: F02 Dementia in other diseases classified elsewhere ("intoxications (T36-T65)")
• Use Additional: G21.19 Other drug induced secondary parkinsonism ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G24.0 Drug induced dystonia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G25.1 Drug-induced tremor ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G25.3 Myoclonus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G25.4 Drug-induced chorea ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G25.61 Drug induced tics ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G25.7 Other and unspecified drug induced movement disorders ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G40.5 Epileptic seizures related to external causes ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G43 Migraine ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G44.4 Drug-induced headache, not elsewhere classified ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G62.0 Drug-induced polyneuropathy ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G71.14 Drug induced myotonia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: G72.0 Drug-induced myopathy ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: G92.8 Other toxic encephalopathy ("poisoning due to drug or toxin, if applicable, (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: G92.8 Other toxic encephalopathy ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: G92.9 Unspecified toxic encephalopathy ("poisoning due to drug or toxin, if applicable, (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: G92.9 Unspecified toxic encephalopathy ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: H21.81 Floppy iris syndrome ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: H26.3 Drug-induced cataract ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: H35.38 Toxic maculopathy ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: H35.38 Toxic maculopathy ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: H40.6 Glaucoma secondary to drugs ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: H91.0 Ototoxic hearing loss ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: H91.0 Ototoxic hearing loss ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: I42.7 Cardiomyopathy due to drug and external agent ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: I42.7 Cardiomyopathy due to drug and external agent ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: I47.21 Torsades de pointes ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: I95.2 Hypotension due to drugs ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: J70.2 Acute drug-induced interstitial lung disorders ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: J70.3 Chronic drug-induced interstitial lung disorders ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: J70.4 Drug-induced interstitial lung disorders, unspecified ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: J84.89 Other specified interstitial pulmonary diseases ("code, for adverse effect, to identify drug (T36-T50 with fifth or sixth character 5), if drug-induced")
• Use Additional: K12.32 Oral mucositis (ulcerative) due to other drugs ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: K22.1 Ulcer of esophagus ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: K22.1 Ulcer of esophagus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: K52.1 Toxic gastroenteritis and colitis ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: K59.03 Drug induced constipation ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: K71 Toxic liver disease ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: K71 Toxic liver disease ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: K85.3 Drug induced acute pancreatitis ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L10.5 Drug-induced pemphigus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L12.31 Epidermolysis bullosa due to drug ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L23.3 Allergic contact dermatitis due to drugs in contact with skin ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L24.4 Irritant contact dermatitis due to drugs in contact with skin ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L25.1 Unspecified contact dermatitis due to drugs in contact with skin ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L27.0 Generalized skin eruption due to drugs and medicaments taken internally ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L27.1 Localized skin eruption due to drugs and medicaments taken internally ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L29.81 Cholestatic pruritus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L43.2 Lichenoid drug reaction ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L51 Erythema multiforme ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: L53.0 Toxic erythema ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: L53.0 Toxic erythema ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L56.0 Drug phototoxic response ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L56.1 Drug photoallergic response ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L64.0 Drug-induced androgenic alopecia ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L65 Other nonscarring hair loss ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L71 Rosacea ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: L93 Lupus erythematosus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M1A.2 Drug-induced chronic gout ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M10.2 Drug-induced gout ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M32.0 Drug-induced systemic lupus erythematosus ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: M34.2 Systemic sclerosis induced by drug and chemical ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: M34.2 Systemic sclerosis induced by drug and chemical ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M80.8 Other osteoporosis with current pathological fracture ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M81.8 Other osteoporosis without current pathological fracture ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M83.5 Other drug-induced osteomalacia in adults ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Use Additional: M87.1 Osteonecrosis due to drugs ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: N14 Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: N14 Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")
• Code First: P58.4 Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn ("poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)")
• Use Additional: P58.4 Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn ("code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)")

Nearby codes

• T44.5X1 Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional)
• T44.5X1A Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), initial encounter
• T44.5X1D Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
• T44.5X1S Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), sequela
• T44.5X2 Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm
• T44.5X2A Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter (this code)
• T44.5X2D Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter
• T44.5X2S Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela
• T44.5X3 Poisoning by predominantly beta-adrenoreceptor agonists, assault
• T44.5X3A Poisoning by predominantly beta-adrenoreceptor agonists, assault, initial encounter
• T44.5X3D Poisoning by predominantly beta-adrenoreceptor agonists, assault, subsequent encounter